|
Apoc incident # (b)(4).Apoc labeling was evaluated during the investigation as pertaining to the event.The investigation was completed on 09/26/2016.Retain product was tested and functioning according to specification.Return product was not available.Investigation: a review of the device history record confirmed the cartridge lot passed finished goods release criteria.Twenty retained cartridges from g3+ lot d16037 were tested using whole blood.The customer observation of po2 star-out results, discrepant pco2 or results related to discrepant bicarbonate results were not reproduced.The results of testing met the acceptance criteria found in q04.01.003 rev.Y, appendix 1- product complaint level 2 and level 3 investigation procedure.The investigation confirmed the cartridge lots are performing to specification.No deficiency identified.Assessment: the complaint investigation concluded there was no product deficiency and that the i-stat cartridge lot is meeting specification.Hco3 is a calculated value based on the measured ph and pco2 (log hco3 = ph + log pco2 - 7.608).There are no repeats on any sample.Samples 1, 4 and 7 are consistent for ph, pco2 and po2 and samples 2,3 5 and 6 are consistent for ph, pco2 and po2.It was unknown if there were bubbles in any of the samples.
|
|
On (b)(6) 2015, abbott point of care was contacted by a customer regarding i-stat g3+ cartridges that yielded suspected discrepant pco2 results on a patient.There was no additional patient information at the time of this report.Return product is not available for investigation.(b)(6).At the time of the event there was no indication of a product malfunction based on the information provided and assessed by apoc, however this mdr is a retrospective filing in response to an observation from an fda inspection conducted may 8th to 12th, 2017 at abbott point of care (b)(4).
|